Page last updated: 2024-10-30

losartan and Carcinoma, Intraductal, Noninfiltrating

losartan has been researched along with Carcinoma, Intraductal, Noninfiltrating in 1 studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Carcinoma, Intraductal, Noninfiltrating: A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Coulson, R1
Liew, SH1
Connelly, AA1
Yee, NS1
Deb, S1
Kumar, B1
Vargas, AC1
O'Toole, SA1
Parslow, AC1
Poh, A1
Putoczki, T1
Morrow, RJ1
Alorro, M1
Lazarus, KA1
Yeap, EFW1
Walton, KL1
Harrison, CA1
Hannan, NJ1
George, AJ1
Clyne, CD1
Ernst, M1
Allen, AM1
Chand, AL1

Other Studies

1 other study available for losartan and Carcinoma, Intraductal, Noninfiltrating

ArticleYear
The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma.
    Oncotarget, 2017, Mar-21, Volume: 8, Issue:12

    Topics: 9,10-Dimethyl-1,2-benzanthracene; Angiotensin II Type 1 Receptor Blockers; Animals; Biopsy; Breast N

2017